A5007972486- Hepatitis C virus research
- Monoclonal and Polyclonal Antibodies Research
- Hepatitis B Virus Studies
- Glycosylation and Glycoproteins Research
- Liver Disease Diagnosis and Treatment
- HIV Research and Treatment
- Systemic Lupus Erythematosus Research
- vaccines and immunoinformatics approaches
- Hepatitis Viruses Studies and Epidemiology
Johns Hopkins University
2017-2019
Johns Hopkins Medicine
2017-2019
Significance More than 71 million people are infected with HCV, and eradication of this pandemic will likely require a vaccine. Induction broadly neutralizing monoclonal antibodies (bNAbs) is goal vaccine development, but no single bNAb neutralizes all strains HCV. Here, we measured activity 35 combinations (NAbs), showing that some NAbs form greater breadth any individual bNAb. One combination was also exceptionally potent because it blocks virus binding to three different HCV receptors....
Worldwide, more than 70 million people are infected with hepatitis C virus (HCV), which is a leading cause of hepatocellular carcinoma and liver transplantation. Despite the development potent direct acting antivirals (DAAs) for HCV treatment, vaccine urgently needed due to high cost treatment possibility reinfection after cure. Induction multiple broadly neutralizing antibodies (bNAbs) that target distinct epitopes on envelope proteins one approach development. However, antigenic sites...
A vaccine for hepatitis C virus (HCV) is urgently needed. Development of broadly neutralizing plasma antibodies during acute infection associated with HCV clearance, but the viral epitopes these are unknown. Identifying could define specificity and function (NAbs) that should be induced by a vaccine. Here, we present development application high-throughput method deconvolutes polyclonal anti-HCV NAbs in plasma, delineating epitope specificities acute-infection 44 humans subsequent clearance...